BEIJING, March 4, 2024 /PRNewswire/ — A news report from chinadaily.com.cn:
jwplayer(‘myplayer1’).setup(file: ‘https://mma.prnasia.com/media2/2353482/1.mp4’, image: ‘https://mma.prnasia.com/media2/2353482/1.mp4?p=medium’, autostart:’false’, stretching : ‘uniform’, width: ‘512’, height: ‘288’);
Is the Chinese market still attractive to high-tech firms from developed countries? Will the decline of demographic dividend affect China’s growth? And how will China ensure high-quality development? Click the video to find the answers from Justin Yifu Lin, a member of the Standing Committee of the 14th CPPCC National Committee, vice-chairman of the Committee on Economic Affairs of the CPPCC National Committee and dean of Peking University’s Institute of New Structural Economics.
ข่าวที่เกี่ยวข้อง
- The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
- Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
- 2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
- 2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
